Elizabeth E. Liu

Elizabeth E. Liu

Auto-generated profile, based on publicly available information

Elizabeth E. Liu

CardioVascular Institute and Division of Cardiology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ELEmily S. Lau
Emily S. Lau
JMJenna N. McNeill
Jenna N. McNeill
SPSamantha M. Paniagua
Samantha M. Paniagua
ELElizabeth E. Liu
Elizabeth E. Liu
JWJessica K. Wang
Jessica K. Wang
JHJennifer E. Ho
Jennifer E. Ho
Background: Men are at higher risk for serious complications related to COVID-19 infection than women. More robust immune activation in women has been proposed to contribute to decreased disease severity, although systemic inflammation has been associated with worse outcomes in COVID-19 infection. Whether systemic inflammation contributes to sex differences in COVID-19 infection is not known. Study design and methods: We examined sex differences in inflammatory markers among 453 men (mean age 61) and 328 women (mean age 62) hospitalized with COVID-19 infection at the Massachusetts General Hospital from March 8 to April 27, 2020. Multivariable linear regression models were used to examine the association of sex with initial and peak inflammatory markers. Exploratory analyses examined the association of sex and inflammatory markers with 28-day clinical outcomes using multivariable logistic regression. Results: Initial and peak CRP were higher in men compared with women after adjustment for baseline differences (initial CRP: ß 0.29, SE 0.07, p = 0.0001; peak CRP: ß 0.31, SE 0.07, p<0.0001) with similar findings for IL-6, PCT, and ferritin (p<0.05 for all). Men had greater than 1.5-greater odds of dying compared with women (OR 1.71, 95% CI 1.04–2.80, p = 0.03). Sex modified the association of peak CRP with both death and ICU admission, with stronger associations observed in men compared with women (death: OR 9.19, 95% CI 4.29–19.7, p <0.0001 in men vs OR 2.81, 95% CI 1.52–5.18, p = 0.009 in women, Pinteraction = 0.02). Conclusions: In a sample of 781 men and women hospitalized with COVID-19 infection, men exhibited more robust inflammatory activation as evidenced by higher initial and peak inflammatory markers, as well as worse clinical outcomes. Better understanding of sex differences in immune responses to COVID-19 infection may shed light on the pathophysiology of COVID-19 infection.

9 February 2022 in Circulation: Heart Failure
Verified
Journal Article
Closed access
PDF file
EZEmily K. Zern
Emily K. Zern
DWDongyu Wang
Dongyu Wang
PRPaula Rambarat
Paula Rambarat
SBSamuel Bernard
Samuel Bernard
SPSamantha M. Paniagua
Samantha M. Paniagua
JHJennifer E. Ho
Jennifer E. Ho
Background: The pulmonary artery pulsatility index (PAPi), calculated from the ratio of the pulmonary artery pulse pressure to right atrial pressure, is a predictor of right ventricular failure after inferior myocardial infarction and left ventricular assist device implantation. Whether PAPi is associated with adverse outcomes across a heterogeneous population is unknown. Methods: We examined consecutive patients undergoing right heart catheterization between 2005 and 2016 in a hospital-based cohort. Multivariable Cox models were utilized to examine the association between PAPi and all-cause mortality, major adverse cardiac events, and heart failure hospitalizations. Results: We studied 8285 individuals (mean age 63 years, 39% women) with median PAPi across quartiles 1.7, 2.8, 4.2, and 8.7, who were followed over a mean follow-up of 6.7±3.3 years. Patients in the lowest PAPi quartile had a 60% greater risk of death compared with the highest quartile (multivariable-adjusted hazard ratio, 1.60 [95% CI, 1.36–1.88], P <0.001) and a higher risk of major adverse cardiac events and heart failure hospitalizations (hazard ratio, 1.80 [95% CI, 1.56–2.07], P <0.001 and hazard ratio, 2.08 [95% CI, 1.76–2.47], P <0.001, respectively). Of note, patients in quartiles 2 and 3 also had increased risk of cardiovascular events compared with quartile 4 (multivariable P <0.05 for all). Conclusions: Compared with the highest PAPi quartile, patients in PAPi quartiles 1 to 3 had a greater risk of all-cause mortality, major adverse cardiac events, and heart failure hospitalizations, with greatest risk observed in the lowest quartile. A low PAPi, even at values higher than previously reported, may serve an important role in identifying high-risk individuals across a broad spectrum of cardiovascular disease.

1 January 2020 in JAMA Cardiology
Verified
Journal Article
Open access
PDF file
ELEmily S. Lau
Emily S. Lau
TCThomas Cunningham
Thomas Cunningham
KHKathryn M. Hardin
Kathryn M. Hardin
ELElizabeth Liu
Elizabeth Liu
RMRajeev Malhotra
Rajeev Malhotra
JHJennifer E. Ho
Jennifer E. Ho
Heart failure with preserved ejection fraction (HFpEF) is an important public health concern. It accounts for more than 1 million hospitalizations each year, and its prevalence is expected to exceed heart failure with reduced ejection fraction in the near term.1 Its clinical phenotype is highly heterogeneous, making its diagnosis and treatment challenging. To date, to our knowledge, there is no uniform definition and no existing targeted pharmacotherapies have been shown to improve outcomes in clinical trials.2 Sex differences in HFpEF have been well described and likely contribute to its clinical heterogeneity.3,4 The prevalence of HFpEF is markedly higher in women than men.5 Differences in cardiovascular structure, adaptations to physiologic stress, and comorbidity burden have all been proposed to explain this difference, but true mechanistic understanding is lacking, limited by the paucity of women enrolled in heart failure trials and the neutrality of these trials.6 Prior studies have shown that hypertension and aging preferentially predispose women to the development of left ventricular (LV) hypertrophy.7,8 Separately, a recent study demonstrated that cardiometabolic traits are more strongly associated with risk of future HFpEF compared with heart failure with reduced ejection fraction, particularly in women.9

1 January 2021 in Obesity Research & Clinical Practice
Verified
Journal Article
Closed access
JMJenna N. McNeill
Jenna N. McNeill
ELEmily S. Lau
Emily S. Lau
SPSamantha M. Paniagua
Samantha M. Paniagua
ELElizabeth E. Liu
Elizabeth E. Liu
JWJessica K. Wang
Jessica K. Wang
JHJennifer E. Ho
Jennifer E. Ho

19 January 2021 in Circulation
Verified
Journal Article
Closed access
PDF file
TCTimothy W. Churchill
Timothy W. Churchill
SLShawn X. Li
Shawn X. Li
LCLisa Curreri
Lisa Curreri
EZEmily K. Zern
Emily K. Zern
ELEmily S. Lau
Emily S. Lau
JHJennifer E. Ho
Jennifer E. Ho

15 March 2022 in JACC: Cardiooncology
Verified
Journal Article
Open access
ELElizabeth E. Liu
Elizabeth E. Liu
NSNavin Suthahar
Navin Suthahar
SPSamantha M. Paniagua
Samantha M. Paniagua
DWDongyu Wang
Dongyu Wang
ELEmily S. Lau
Emily S. Lau
JHJennifer E. Ho
Jennifer E. Ho
Obesity and cardiometabolic dysfunction have been associated with cancer risk and severity. Underlying mechanisms remain unclear. The aim of this study was to examine associations of obesity and related cardiometabolic traits with incident cancer. FHS (Framingham Heart Study) and PREVEND (Prevention of Renal and Vascular End-Stage Disease) study participants without prevalent cancer were studied, examining associations of obesity, body mass index (BMI), waist circumference, visceral adipose tissue (VAT) and subcutaneous adipose tissue depots, and C-reactive protein (CRP) with future cancer in Cox models. Among 20,667 participants (mean age 50 years, 53% women), 2,619 cancer events were observed over a median follow-up duration of 15 years. Obesity was associated with increased risk for future gastrointestinal (HR: 1.30; 95% CI: 1.05-1.60), gynecologic (HR: 1.62; 95% CI: 1.08-2.45), and breast (HR: 1.32; 95% CI: 1.05-1.66) cancer and lower risk for lung cancer (HR: 0.62; 95% CI: 0.44-0.87). Similarly, waist circumference was associated with increased risk for overall, gastrointestinal, and gynecologic but not lung cancer. VAT but not subcutaneous adipose tissue was associated with risk for overall cancer (HR: 1.22; 95% CI: 1.05-1.43), lung cancer (HR: 1.92; 95% CI: 1.01-3.66), and melanoma (HR: 1.56; 95% CI: 1.02-2.38) independent of BMI. Last, higher CRP levels were associated with higher risk for overall, colorectal, and lung cancer (P < 0.05 for all). Obesity and abdominal adiposity are associated with future risk for specific cancers (eg, gastrointestinal, gynecologic). Although obesity was associated with lower risk for lung cancer, greater VAT and CRP were associated with higher lung cancer risk after adjusting for BMI.